Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment

MT Newswires Live

Oct 21

Verrica Pharmaceuticals (VRCA) said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.

The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.

The company plans to submit the application as early as Q4 2026.

YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.

Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577963088"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577963088\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577963088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577963088","market":"fut","top_or_hot":-1,"title":"Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment","media":"MT Newswires Live","content":"<html><body><p> Verrica Pharmaceuticals (VRCA) said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.</p><p>The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.</p><p>The company plans to submit the application as early as Q4 2026.</p><p>YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.</p><p>Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-21 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Verrica Pharmaceuticals (VRCA) said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.</p><p>The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.</p><p>The company plans to submit the application as early as Q4 2026.</p><p>YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.</p><p>Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577963088","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577963088","pubTimestamp":1760994694,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verrica Pharmaceuticals  said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.The company plans to submit the application as early as Q4 2026.YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药","BK4156":"煤与消费用燃料"},"translate_title":"Verrica Pharmaceuticals获准申请欧盟批准软体动物治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":1},"content_text":"Verrica Pharmaceuticals (VRCA) said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.The company plans to submit the application as early as Q4 2026.YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}